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Introduction
About 1.2 million new cases of lung can­
cer occur annually worldwide. Approxi­
mately 35 % of patients with non­small 
cell lung cancer (NSCLC) are diagnosed 
with stage III disease [1]. Of the stage III 
subgroup, only about 20 % of patients 
can be treated with surgery; the majori­
ty of patients may choose radiotherapy 
(RT) for local treatment, and meta­anal­
ysis indicates that combined chemother­
apy and radiotherapy (CCRT) has be­
come the standard of care for this group 
of patients, with good outcomes [2]. Spe­
cifically, among patients who under­
went CCRT with a standard dose of ra­
diation (> 60 Gy), the complete remission 
rate ranged from 10 to 60 %, with a 5­year 
survival rate of 5–23 % [3]. Patients sur­
viving for 6–12 months had a statistically 
significantly increased survival rate when 
the intrathoracic tumor was controlled. 
Patients treated with 50–60 Gy showing 
tumor control had a 3­year survival rate 
of 22 %, compared with 10 % for patients 
with intrathoracic failure [4], suggesting 
that local intrathoracic control may be 
predictive of patient survival. Therefore, 
it is important to enhance the radiosensi­
tivity of lung cancer cells, which may af­
fect local control and subsequent surviv­
al. In this study, we attempted to analyze 
the environmental changes after RT that 
increase the likelihood of the resistance of 
cancer cells to RT.
Blood and lymphatic vascular system 
development and maintenance are cou­
pled through multiple growth factors and 
receptors expressed on blood and lym­
phatic endothelial cells (BECs and LECs, 
respectively). Vascular endothelial growth 
factors A and C (VEGF­A and VEGF­C, 
respectively) are two major growth fac­
tors that promote endothelial cell prolif­
eration, migration, and induction of per­
meability. VEGF­C binding to VEGF re­
ceptor 3 (VEGFR­3) induces LEC prolifer­
ation and lymphatic vascular hyperplasia 
[5, 6]. VEGF­C can also bind to VEGFR­2, 
eliciting a response that is similar to that 
induced by VEGF­A but less potent [7].
The expression of VEGF­C and VEG­
FR­3 in lung cancer tumor cells was sig­
nificantly associated with more advanced 
regional lymph node metastasis [8–10]. 
Previous studies also demonstrated that 
radiation not only induced angiogenesis 
but also caused lymphangiogenesis [11]. 
For example, Nathanson et al. reported 
that subtherapeutic hyperthermia or ra­
diation increased lymphatic flow from 
tumors, which was associated with an in­
crease in metastasis of melanoma [12]. 
Talmadge et al. also showed that sublethal 
dose irradiation activated genes or signal 
pathways that induced functional chang­
es that increased the survival or metastasis 
of cancer cells [13]. Moreover, radiation 
of tumor cells induced vascular or micro­
environment changes that enhanced cap­
illary invasion capacity [14, 15]. In the 
present study, we investigated the mech­
anism and consequences of irradiation­




The human lung cell lines A549 and 
H1299 were obtained from the Ameri­
can Type Culture Collection (Manassas, 
Va.) and were maintained in Dulbecco’s 
modified Eagle medium (DMEM) or RP­
MI supplemented with nonessential ami­
no acids, l­glutamine, a twofold vitamin 
solution, sodium pyruvate, 10 % fetal bo­
vine serum, penicillin, and streptomycin. 
Cells were cultured at 37 °C in a humidi­
fied atmosphere of 5 % CO2 and 95 % air.
Establishment of lung cancer 
xenografts and irradiation
Male SCID mice (5–6 weeks old) were ob­
tained from the National Taiwan Univer­
sity Animal Center, Taipei, Taiwan. To es­
tablish the xenografts, 1 × 106 A549 cells 
were injected subcutaneously into the 
right hind limb. At 10 days postimplanta­
tion, mice were immobilized in a custom­
ized harness that exposed the right hind 
leg. The remainder of the body was shield­
ed by five times the half­value thickness of 
lead. A cobalt­60 unit was used to irradi­
ate the primary tumor with 25 or 50 Gy (5­
Gy or 10­Gy daily fractions, at a dose rate 
of 1 Gy/min).
On postimplantation day 9, tumor vol­
umes were calculated every 3 days using a 
standard formula: width2 × length/2. Tu­
mors were harvested at the time of sac­
rifice 14 days after completion of the ra­
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diotherapy and fixed in 10 % neutral buff­
ered formalin and processed for immu­
nohistochemical evaluations. All mice 
were group­housed under a fixed light–
dark cycle (12 h of light and 12 h of dark­
ness) with ad libitum access to sterilized 
food and water. All experimental proce­
dures were performed in accordance with 
protocols approved by the Committee of 
Experimental Animal Management at 
the College of Medicine, National Taiwan 
University.
Immunohistochemistry analysis
All tissues were fixed in 10 % neutral buff­
ered formalin and embedded in paraffin 
using standard protocols. Immunohisto­
chemistry (IHC) analysis was performed 
on a single representative block from 
each case. Tissue sections (5 μm) were 
dewaxed, and antigen retrieval was per­
formed in a citrate buffer (pH 6) using an 
electric pressure cooker set at 120 °C for 
5 min as previously described (Choi et al. 
2005). Sections were incubated for 5 min 
in 3 % hydrogen peroxide to quench en­
dogenous tissue peroxidase. The sections 
were incubated in antibodies specific for 
the lymphatic endothelial marker, D2­40 
antibodies (1:200 dilution; Biocompare, 
San Francisco, Calif.), for 60 min at room 
temperature. After washing unbound 
primary antibody, sections were treated 
with biotinylated secondary antibodies 
followed by avidin coupled to biotinylat­
ed HRP at room temperature according 
to the manufacturer’s instructions (DA­
KO, Carpinteria, Calif.). Immunohisto­
chemical reactions were developed with 
diaminobenzidine as the chromogen­
ic peroxidase substrate. Sections were 
counterstained with hematoxylin. Speci­
ficity was verified by negative control re­
actions that did not contain primary anti­
bodies as well as by appropriate cytoplas­




Immunohistochemical reactions for D2­
40 were analyzed at low magnification 
(× 40), and lymphatic vessels were count­
ed in five representative high­magnifica­
tion (× 400; 0.152 mm2; 0.44­mm diam­
eter) fields. Single immunoreactive lym­
phatic endothelial cells, or lymphatic en­
dothelial cell clusters separate from oth­
er microlymphatic vessels, were counted 
as individual microlymphatic vessels. The 
mean visual microlymphatic vessel densi­
ty (MLVD) for D2­40 was calculated.
Culture of HUVECs and LECs
Human umbilical vein endothelial cells 
(HUVECs) were purchased from the 
Food Industry Research and Develop­
ment Institute and cultured in M199 me­
dium (Life Technologies, Carlsbad, Ca­
lif.) supplemented with 20 % fetal bovine 
serum, endothelial cell growth supple­
ment (Millipore, Billerica, Mass.), hepa­
rin, l­glutamine, penicillin, and strepto­
mycin. Human lymphatic endothelial cell 
(LECs) were isolated from human lymph 
nodes (ScienCell, Carlsbad, Calif.) and 
cultured in endothelial cell medium (Sci­
enCell). The cells were cultured at 37 °C 
in a humidified atmosphere of 5 % CO2 
and 95 % air.
Irradiation protocol
Cell culture plates were irradiated with 
different doses of radiation (0–10 Gy) us­
ing a cobalt­60 unit. The source–skin dis­
tance technique was set at 80 cm at the 
bottom of the flask. The dose rate was 
1 Gy/min. Dosimetry was performed with 
an ionization chamber.
Western blot analysis
After cells were treated with various radi­
ation doses and drugs, total protein was 
collected at different times. Protein was 
extracted using Mammalian Protein Ex­
traction Reagent (M­PER; Pierce, Rock­
ford, Ill.). An equal amount of protein 
from each cell line was loaded per lane 
and separated on a 10 % sodium dodec­
yl sulfate (SDS)–Tris glycine polyacryl­
amide gel electrophoresis (PAGE) gel. 
Gels were transferred onto nitrocellu­
lose membranes (Novex, San Diego, Ca­
lif.) and blocked overnight by incubat­
ing with 1 × Tris­buffered saline contain­
ing 0.1 % Tween and 5 % nonfat dry milk. 
Membranes were probed with antibod­
ies against phospho­Akt (p­Akt; Cell Sig­
naling, Beverly, Mass.), phospho­mTOR 
(p­mTOR; Novus International, St. Lou­
is, Mo.), phospho­eIF4E (p­4EBP), phos­
pho–p70 ribosomal protein S6 kinas­
es (p­p70S6K; Cell Signaling), phos­
pho–eukaryotic translation initiation fac­
tor 4E (p­eIF4E; Cell Signaling), VEGF­
C (Zymed Laboratories, South San Fran­
cisco, Calif.), Akt, mTOR, 4EBP, eIF4E, 
and actin (all from Chemicon Interna­
tional, Temecula, Calif.). Bound antibod­
ies were then detected using the appro­
priate peroxidase­coupled secondary an­
tibodies, followed by incubation with an 
enhanced chemiluminescence detection 
system (ECL; Boehringer Mannheim, 
Mannheim, Germany).
Enzyme-linked immunosorbent 
assay to detect secreted VEGF-C
Cell culture supernatant was collected af­
ter culturing A549 cells in completed cul­
ture medium for 24 h after irradiation. 
VEGF­C secretion was measured in the 
cell culture supernatant using a commer­
cial enzyme­linked immunosorbent assay 
(ELISA) kit (R&D Systems, Minneapolis, 
Minn.) according to the manufacturer’s 
protocol. Color intensity was measured 
by a plate reader at 450 nm. Data repre­
sent the average of three different assays.
Reverse transcription–
polymerase chain reaction
Reverse transcription (RT) of RNA was 
performed in a final reaction volume of 
20 µl containing 5 µg of total RNA in Mo­
loney murine leukemia virus (MMLV) re­
verse transcriptase buffer that contained 
10  mM dithiothreitol, dNTPs (2.5  mM 
each), 1 mM (dT) primer, and 200 U of 
MMLV reverse transcriptase (Prome­
ga, Madison, Wis.). The reaction mix­
ture was incubated at 37 °C for 2 h, and 
was terminated by heating at 70 °C for 
10 min. A portion of the reaction mix­
ture was then amplified by PCR with the 
following primer pairs: VEGF­C, sense 
5′­CAGTTACGGTCTGTGTCCAGT­
GTAG­3′ and antisense 5′­GGACA­
CACATGGAGGTTTAA­3′; β­actin, 
sense 5′­ ATCCGCAAAGACCTG­
TACGC­3′ and antisense 5′­TGTGTG­
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GACTTGGGAGAGGA­3′. A total of 
30 cycles were performed. The prod­
ucts were separated on 2 % agarose gels, 
stained with 1 mg/ml ethidium bromide, 
and visualized using a UVP GDS­7900 
digital imaging system. The results were 
confirmed by conducting at least three in­
dependent experiments.
Transfection of small 
interfering RNA
Small interfering RNA (siRNA) duplex­
es specific for VEGF­C or Akt were pur­
chased from Santa Cruz Biotechnology 
(Santa Cruz, Calif.); control siRNAs with 
sequences that do not target any gene 
product were obtained from Invitrogen 
(Carlsbad, Calif.). Cells were transfect­
ed with 25 nM VEGF­C siRNA, Akt siR­
NA, or control siRNA in serum­free Op­
ti­MEM using the oligofectamine method 
(Invitrogen) for 1 h at 37 °C. After chang­
ing the culture medium, cells were cul­
tured for 24 h at 37 °C prior to further ex­
periments.
Conditioned media collection
A549 (1 × 105 cells) cells expressing con­
trol or VEGF­C siRNA were cultured in 
a 6­cm dish overnight, washed two times 
with PBS, and then incubated in medi­
um before exposure to 5­Gy irradiation. 
Conditioned medium (CM) was harvest­
ed at 24 h after irradiation. The origin of 
CM was designated as the following: (1) 
non­irradiated A549 CM, (2) irradiated 
A549 CM, (3) irradiated VEGF­C­siRNA 
A549 CM, and (4) irradiated control­siR­
NA A549 CM.
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Abstract
Background. The present study was under-
taken to investigate whether radiation in-
duces the expression of vascular endothelial 
growth factor C (VEGF-C) through activation 
of the PI3K/Akt/mTOR pathway,subsequently 
affecting endothelial cells.
Materials and methods. Radiotherapy-in-
duced tumor micro-lymphatic vessel density 
(MLVD) was determined in a lung cancer xe-
nograft model established in SCID mice. The 
protein expression and phosphorylation of 
members of the PI3K/Akt/mTOR pathway and 
VEGF-C secretion and mRNA expression in ir-
radiated lung cancer cells were assessed by 
Western blot analysis, enzyme-linked immu-
nosorbent assays (ELISAs), and reverse tran-
scriptase–polymerase chain reaction (RT-
PCR). Moreover, specific chemical inhibitors 
were used to evaluate the role of the PI3K/
Akt/mTOR signaling pathway. Conditioned 
medium (CM) from irradiated control-siRNA 
or VEGF-C-siRNA-expressing A549 cells was 
used to evaluate the proliferation of endothe-
lial cells by the MTT assay.
Results. Radiation increased VEGF-C expres-
sion in a dose-dependent manner over time 
at the protein but not at the mRNA level. Ra-
diation also up-regulated the phosphoryla-
tion of Akt, mTOR, 4EBP, and eIF4E, but not of 
p70S6K. Radiation-induced VEGF-C expres-
sion was down-regulated by LY294002 and 
rapamycin (both p < 0.05). Furthermore, CM 
from irradiated A549 cells enhanced human 
umbilical vein endothelial cell (HUVEC) and 
lymphatic endothelial cell (LEC) proliferation, 
which was not observed with CM from irradi-
ated VEGF-C-siRNA-expressing A549 cells.
Conclusions. Radiation-induced activation 
of the PI3K/Akt/mTOR signaling pathway in-
creases VEGF-C expression in lung cancer 
cells, thereby promoting endothelial cell pro-
liferation.
Keywords
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Strahleninduzierte VEGF-C-Expression und endotheliale Zellteilung bei Lungenkrebs
Zusammenfassung
Hintergrund und Ziel. Die vorliegende Stu-
die untersucht, ob die Strahlung die Expres-
sion von VEGF-C (vascular endothelial growth 
factor C) mittels Aktivierung des PI3K/Akt/
mTOR-Signalwegs induziert und anschlie-
ßend die endothelialen Zellen beeinflusst.
Methoden und Material. Die durch Strah-
lentherapie induzierte Mikrolymphgefäß-
dichte (MLVD) im Tumor wurde in einem Lun-
genkrebs-Xenograftmodell mit SCID-Mäu-
sen ermittelt. Die Proteinexpression, die 
Phosphorylierung der Mitglieder des PI3K/
Akt/mTOR-Signalwegs und die Expression-
der VEGF-C-Sekretion und mRNA-Expression 
in bestrahlten Lungenkrebszellen wurden je-
weils mittels Westernblot-Analyse, ELISA (en-
zyme-linked immunosorbent assays) und RT-
PCR (Reverse-Transkriptase-Polymeraseket-
tenreaktion)bewertet. Außerdem wurden 
spezifische chemische Inhibitoren verwen-
det, um die Rolle des PI3K/Akt/mTOR-Sig-
nalwegs auszuwerten. Konditioniertes Me-
dium (CM) aus bestrahlten Kontroll-siRNA-ex-
primierenden und ausunbestrahlten VEGF-
C-siRNA-exprimierenden A549-Zellen wurde 
benutzt, um die Proliferation von Endothel-
zellen mittels MTT-Assay zu bewerten.
Ergebnisse. Strahlung erhöht die dosis-
abhängige und zeitabhängige VEGF-C-Ex-
pression auf Protein- anstatt auf mRNA-Ebe-
ne. Durch die Bestrahlung wurde die Phos-
phorylierung von Akt, mTOR, 4EBP und eIF4E 
hochreguliert, nicht jedoch von p70S6K. Die 
trahleninduzierte VEGF-C-Expression wurde 
durch LY294002 und Rapamycin herunterre-
guliert (beide p < 0,05). Des Weiteren fördert 
CM aus den unbestrahlten A549-Zellen die 
Proliferation der menschlichen Nabelvenen-
endothelzellen (HUVECs) und der lymphati-
schen Endothelzellen (LECs). CM aus den un-
bestrahlten und VEGF-C-iRNA-exprimieren-
den A549-Zellen hat jedoch keine prolifera-
tionsfördernde Wirkung.
Schlussfolgerungen. Die strahleninduzierte 
Aktivierung des PI3K/Akt/mTOR-Signalwegs 
kann die Expression des VEGF-C in Lungen-
krebszellen erhöhen und die Proliferation der 
Endothelzellen fördern.
Schlüsselwörter
Strahlung · Vaskulärer endothelialer 
Wachstumsfaktor C · Lungenkrebszellen · 
Endothelzellen · PI3K/Akt/mTOR-Signalweg
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Cell proliferation assay
Cells were cultured in 96­well plates at a 
density of 5,000 cells/well. The quanti­
ty of viable cells was estimated by a col­
orimetric assay using 3­(4,5­dimethylthi­
azol­2­yl)­2,5­diphenyltetrazolium bro­
mide (MTT). MTT (10 µl of 5 mg/ml so­
lution, Sigma, Germany) was added to 
each well and incubated for 4 h at 37 °C. 
The cells were then treated with 40 µl/well 
dimethyl sulfoxide (DMSO) and incubat­
ed for 60 min at 37 °C. The absorbance 
of each well was determined in an ELI­
SA plate reader using an activation wave­
length of 570 nm and a reference wave­
length of 630 nm. The percentage of vi­
able cells was determined by comparison 
with untreated control cells.
Statistical analysis
All data presented are the mean ± stan­
dard deviation of experiments repeated 
three or more times. A paired t­test was 
used to evaluate statistically significant 
differences between indicated groups in 
specified tests; p values < 0.05 were con­
sidered statistically significant.
Results
Sublethal RT dose significantly 
increased tumor MLVD in 
SCID mice bearing ectopic 
lung cancer xenografts
As shown in .  Fig.  1a, 5 fractions of 
10  Gy significantly suppressed the tu­
mor growth, and 5 fractions of 5 Gy had 
a mild therapeutic effect. Analysis of tu­
mor MLVD by examining the expression 
of the lymphatic endothelium vessel­spe­
cific marker D2­40 revealed stronger ex­
pression in the tumors irradiated with 
5 fractions of 5 Gy (. Fig. 1b). Howev­
er, in tumors irradiated with 5 fractions 
of 10 Gy, severe tissue necrosis was ob­
served (. Fig. 1b). As shown in . Fig. 1c, 
the MLVD was significantly higher in tu­
mors irradiated with 5 fractions of 5 Gy. 
However, no MLVD was found in severe 
tissue necrosis of tumors irradiated with 5 
fractions of 10 Gy.
Radiation induced a 
dose-dependent increase in VEGF-C 
expression by lung cancer cells
Due to the proteolytic processing of 
VEGF­C in cancer cells, a 58­kDa VEGF­
C propeptide as well as 31­ and 29­kDa 
secreted VEGF­C peptide levels were 
evaluated by Western blot analysis [16]. 
As compared with the non­irradiated 
cells, those treated with 5­Gy irradiation 
for 24 h had increased VEGF­C expres­
sion in A549 cells (. Fig. 2a). In A549 
and H1299 lung cancer cells, radiation in­
creased VEGF­C expression in a dose­de­
pendent manner (. Fig. 2b). At 24 h after 
exposure to radiation, VEGF­C expres­
sion increased 1.75­, 1.98­, and 2.01­fold 
with 2.5, 5, and 10 Gy, respectively, rela­
tive to the non­irradiated group in A549 
cells (p < 0.05 for cells treated with 2 and 
5 Gy; . Fig. 2c). In addition, the effects of 
5­Gy irradiation on VEGF­C expression 
increased over time relative to the non­
irradiated control cells (.  Fig.  2d and 
e). Moreover, assessment of the soluble 
VEGF­C peptides by ELISA and West­
ern blot analysis revealed their up­regu­
lation after radiation treatment over time 
(. Fig. 2f).


























































Fig. 1 8 a–c Effects of radiotherapy (RT) on tumor lymphatic vessel density. A549 cells were seeded 
in the right legs of SCID mice. a Tumor sizes were measured every 3 days. On day 10, tumors were ex-
posed to sham or to irradiation with 5 Gy × 5 or 10 Gy × 5. Data represent the tumor growth curve. b 
The tumors were removed 14 days after RT, and tumor sections from all the groups were stained with 
an antibody specific for D2-40. The images are representative of three independent experiments. c The 
mean microlymphatic vessels density (MLVD) was counted in ten representative high-power (× 200) 
fields in each group. (*p < 0.05)
Radiation activates the Akt/
mTOR/4EBP/eIF4E signaling 
pathway in the A549 
lung cancer cell line
The effects of radiation on the PI3K/Akt/ 
mTOR signaling pathway were deter­
mined by Western blot analysis. After 
5­Gy radiation, protein samples were col­
lected at 5, 15, 30, 60, and 120 min. Radi­
ation­induced Akt phosphorylation was 
significantly increased by 1.2­fold from 
the control at 15 min (p < 0.01; . Fig. 3a). 
p­mTOR levels were up­regulated 1.2­ 
to 1.4­fold after 5 and 15 min of irradi­
ation, respectively, and this effect per­
sisted for 120 min (. Fig. 3b). p­4EBP, a 
downstream signaling target of mTOR, 
was also significantly increased at 15 min 
(. Fig. 3c); however, p­p70S6K was not 
induced by radiation (.  Fig.  3d). Ad­
ditionally, p­eIF4E gradually increased 
from 5 min after irradiation, peaking at 
1.5­fold at 30 min (. Fig. 3e). Taken to­
gether, these results demonstrated that ra­
diation up­regulated the phosphorylation 
of Akt, mTOR, 4EBP, and eIF4E, but not 
of p70S6K.
Irradiation-induced VEGF-C 
expression was mediated through 
PI3K/Akt/mTOR signaling in the 
A549 lung cancer cell line
To investigate the relationship between 
radiation, the PI3K/Akt/mTOR signal­
ing pathway, and VEGF­C expression, 
we used 10 µM LY294002 as a PI3K/Akt 
inhibitor, 20 μM PD98059 as an extracel­
lular signal­regulated kinase (ERK) inhib­
itor, 1 μM manumycin A as a P38 inhib­
itor, and 20 nM rapamycin as an mTOR 
inhibitor. A549 cells were pretreated with 
these inhibitors 1 h before 5­Gy irradia­
tion. As shown in . Fig. 4a, radiation­in­
duced VEGF­C expression was signifi­
cantly reduced by LY294002 and rapamy­
cin (both p < 0.05), suggesting that PI3K/
Akt and mTOR signaling were required 
for irradiation­induced VEGF­C expres­
sion.
To confirm the relationship between 
PI3K/Akt and mTOR as well as the role 
of Akt in irradiation­induced VEGF­
C expression, we manipulated Akt ex­
pression using Akt siRNA. As shown in 
. Fig. 4b, Akt phosphorylation was aug­
mented by irradiation and blocked by Akt 
siRNA. Furthermore, irradiation­induced 
mTOR phosphorylation and VEGF up­
regulation in A549 cells were inhibited 
by Akt siRNA (. Fig. 4b), indicating that 
PI3K/Akt/mTOR signaling mediates irra­
diation­induced VEGF­C expression.
Analysis of VEGF­C mRNA expres­
sion by RT­PCR revealed no obvious 
changes in VEGF­C mRNA expression 
between the sham and irradiated groups 
(. Fig. 4c), indicating that the effects of 
irradiation on VEGF­C expression were 
at the translational level, but not the tran­
scriptional level.
Irradiation-induced VEGF-C 
expression promotes the 
proliferation of HUVECs and LECs
The effect of irradiation­induced VEGF­
C expression on HUVEC and LEC prolif­
eration was assessed using siRNA specif­
ic for VEGF­C. The inhibition of VEGF­
C siRNA on the VEGF­C levels in the cell 
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Fig. 2 8 a–f Radiation increases VEGF-C expression in lung cancer cells. a VEGF-C expression, includ-
ing a 58-kDa VEGF-C propeptide, as well as the 31- and 29-kDa secreted peptides, increased after 5 Gy 
of irradiation as compared with the non-irradiated group. b The effect of radiation-induced VEGF-C ex-
pression was dose-dependent in A549 and H1299 cell lines. c Quantification of the immunoblot data 
from A549 cells. d The expression of VEGF-C increased over time in A549 cells. e The immunoblot da-
ta in d were quantified. f VEGF-C secretion into the cell culture supernatant was determined by ELISA. 
Data are presented as mean ± SE, n = 3. (*p < 0.05 compared with non-irradiated cells)
culture supernatant was first confirmed 
by ELISA. As shown in . Fig. 5a, VEGF­
C, but not control siRNA, significantly 
reduced the irradiation­induced VEGF­
C expression in A549 cells.
The effect of CM on HUVEC and LEC 
proliferation was next determined using 
the MTT assay. As shown in . Fig. 5b, 
HUVEC proliferation was significantly 
increased by 1.30­fold after culturing HU­
VECs in CM from irradiated A549 cells as 
compared with that from non­irradiated 
A549 cells (p < 0.01). This effect was sig­
nificantly inhibited when HUVECs were 
cultured in CM from VEGF­C siRNA­ex­
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Fig. 3 9 a–e Radiation up-
regulated phosphorylation 
of the Akt/mTOR/4EBP/
eIF4E pathway. a Radiation 
induced phosphorylation 
of Akt over time, peaking 
at 15 min postirradiation. b 
mTOR, c 4EBP, and e eIF4E 
phosphorylation levels in-
creased after irradiation. d 
p-p70S6K was not induced 
by radiation. Data are pre-
sented as mean ± SE, n = 3. 
(*p < 0.05; **p < 0.01)
pressing A549 cells (p = 0.05; . Fig. 5b). 
The CM from irradiated A549 cells also 
increased LEC proliferation by 1.28­fold, 
which was significantly suppressed when 
LECs were cultured in CM derived from 
irradiated VEGF­C­siRNA­expressing 
A549 cells (p = 0.03; . Fig. 5c).
Discussion
Tumor cells can produce multiple growth 
factors to create a microenvironment con­
ducive for BEC and LEC growth. Tumor 
cell progression and metastasis may ben­
efit from cross­talk between tumor cells, 
VECs, and LECs [17, 18]. Radiation has 
antiangiogenic as well as antilymphogen­
ic effects by damaging cell membranes, 
DNA, and endothelial cells, resulting in 
apoptosis. However, radiation also has 
proangiogenic and prolymphogenic ef­
fects either through direct mechanisms or 
through signals that are released by irra­
diated cancer cells and the tumor micro­
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Fig. 4 9 a–c Radiation-
induced VEGF-C expres-
sion is mediated by PI3K/
Akt/mTOR signal transduc-
tion. a Radiation-induced 
VEGF-C expression was 
significantly reduced by 
LY294002 and rapamycin 
as determined by quantifi-
cation of the immunoblot 
data. b Radiation-induced 
Akt and mTOR phosphory-
lation and VEGF-C expres-
sion was inhibited by Akt 
siRNA. c Radiation-induced 
VEGF-C expression was not 
at the transcriptional lev-
el as determined by RT-PCR 
analysis of VEGF-C mRNA. 
Data are presented as 
mean ± SE, n = 3. (*p < 0.05; 
**p < 0.01 compared with 
untreated cells)
environment. Recent studies also demon­
strated a close association between radio­
sensitivity, proangiogenic growth factors, 
and endothelial cell survival; VEGFR in­
hibitors enhance the therapeutic efficacy 
of irradiation in NSCLC by hindering the 
repair of sublethal radiation damage [19].
In the current study, radiation in­
creased VEGF­C expression in a dose­de­
pendent manner over time. Furthermore, 
CM from irradiated A549 cells enhanced 
proliferation of HUVECs and LECs, 
which was ameliorated in irradiated A549 
cells expressing VEGF­C siRNA, suggest­
ing that VEGF­C may play an important 
role in the angiogenic or lymphogenic ef­
fect of radiation in lung cancer. These re­
sults were consistent with those of other 
studies, which reported that radiation can 
both stimulate and inhibit angiogenesis 
through regulation of the proangiogenic 
and antiangiogenic balance [20, 21]. For 
example, Sonveaux et al. [20] found that 
irradiation stimulated migration and tu­
bulogenesis of HUVECs accompanied by 
up­regulation of endothelial nitric oxide 
synthase (eNOS). In human tumor sam­
ples, the clinical relevance of irradiation­
induced angiogenic growth factor expres­
sion has been observed [21]. For example, 
in a study of rectal cancer patients receiv­
ing neoadjuvant RT followed by surgery, 
a significant increase in VEGF expression 
was observed in postradiation specimens 
compared with primary tumor samples 
[21]. Therefore, radiation might induce 
a defense mechanism against radiation 
damage through the activation of a poten­
tial proangiogenic reaction. Most studies 
demonstrated radiation­induced VEGF­
A expression but the novel finding in our 
study is VEGF­C over­expression after ir­
radiation in lung cancer cells.
Several studies have demonstrated 
that radiation can activate various signal­
ing pathways, including the PI3K, MAPK, 
JNK, and NF­κB signaling pathways [22, 
23]. The PI3K/Akt/mTOR signaling path­
way is involved in tumorigenesis, transla­
tion of proteins for cell cycle progression, 
and lung cancer cell proliferation [24, 25]. 
In addition to killing tumor cells, radia­
tion could induce radioprotective signal­
ing. Several studies analyzing the mecha­
nism of radioresistance have demonstrat­
ed that it may be associated with activation 
of the PI3K/Akt/mTOR pathway [26, 27]. 
Sunavala­Dossabhoy et al. [26] observed 
that radiation increased the expression 
of a radioprotective protein, Tousled­like 
kinase 1B (TLK1B), which was preced­
ed by an increase in p­Akt and p­4EBP. 
Irradiation also induced phosphoryla­
tion of Akt and mTOR in a breast cancer 
cell line, which was attenuated by mTOR 
and PI3K inhibitors. These findings sug­
gest that the mTOR inhibitor attenuates 
radiation­induced Akt/mTOR prosur­
vival signaling and enhances the cyto­
toxic effects of radiation in breast cancer 
cells [27]. Moreover, Dionysopoulos et al. 
[28] demonstrated that clinicopathologi­
cal parameters as well as high mTOR and 
CCND1 mRNA expression were associat­
ed with poor patient outcome in localized 
laryngeal cancer. The present study fur­
ther supported that radiation can induce 
phosphorylation of Akt, mTOR, 4EBP, 














































































































































































promotes HUVEC and 
LEC proliferation. a 
VEGF-C in the cell cul-
ture supernatant as 
determined by ELISA. 
b, c The conditioned 
media (CM) from irra-
diated A549 cells al-
so promoted HUVEC 
and LEC proliferation, 
which was significantly 
suppressed when they 
were cultured in CM 
from irradiated A549 
cells expressing VEGF-
C-siRNA. Data are pre-
sented as mean ± SE, 
n = 3. (*p < 0.05)
and eIF4E, indicating that the PI3K/Akt/
mTOR/eIF4E signaling pathway can be 
activated by irradiation.
mTOR, p38, and JNK play important 
roles in the up­regulation of VEGF­C ex­
pression, and inhibition of mTOR by ra­
pamycin has an anti­lymphangiogenic ef­
fect, which inhibited lymphatic metasta­
sis [29]. Also, activation of the PI3k/Akt 
signaling pathway up­regulated VEGF­C 
expression [30]. These observations were 
supported by the present study, which 
found down­regulation of radiation­in­
duced VEGF­C expression after inhibi­
tion of PI3K/AKT by LY294002, sup­
pression of mTOR signaling by rapamy­
cin, and expression of AKT siRNA. More­
over, our study observed that radiation­
induced VEGF­C expression was at the 
translational level but not the transcrip­
tional level. The result is similar to the 
finding of Morfoisse et al. [31]. They dem­
onstrated that transcription­independent 
but translation­dependent up­regulation 
of VEGF­C in hypoxia stimulates lym­
phangiogenesis in tumors.
Conclusion
In conclusion, in NSCLC cells, radiation in-
duced VEGF-C expression at least in part 
through activation of the PI3K/Akt/mTOR 
pathway. In addition to the tumor cell it-
self, the irradiated supernatant promot-
ed HUVEC and LEC proliferation, which 
was inhibited by VEGF-C-siRNA expres-
sion in cancer cells. The clinical implica-
tion of this study is the critical need to 
suppress radiation-enhanced microenvi-
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